Please login to the form below
How can pharma engage with key decision-makers in new, collaborative NHS care models?
Paul Midgley, Sue Thomas, Steve How and Oli Hudson, of Wilmington Healthcare, explore how pharma should adapt its approach
Introduction
Since the publication of the Five Year Forward View, the NHS has undergone rapid structural change. This has resulted in an increasingly complex, multi-layered healthcare system that is seeing some GPs taking on wide-ranging responsibilities in Integrated Care System (ICS) areas.
It has also resulted in a diverse range of stakeholders becoming involved in NHS service planning, with local authority officers taking on some key STP leadership roles, for example, as opposed to clinicians; and the third sector and patient groups becoming increasingly influential.
Shift in GPs’ prescribing power
Many GP surgeries now work collaboratively in networks or hubs, which may have a prescribing arrangement across a Federation, a CCG, an STP, or even across multiple STPs. Consequently, some GPs have grown more influential as they have assumed extra responsibilities following the structural changes.
In order to engage with GPs effectively, pharma needs to define the decision-making power of individual GPs. It also needs to know of any pressures that exist to prescribe in a certain way within a network or hub; what formularies they are on and the size of their local Area Prescribing Committee (APC) footprint.
Based on this knowledge, pharma then needs to segment its key GP customer groups and ensure that it is delivering the appropriate message and deploying the right level of resource to each type of GP. This should involve assigning one senior level executive to manage the relationship with a particularly influential GP.
Group consensus is key for STPs
STPs were introduced to build on the work of the Vanguards and implement a place-based care system that incorporates both health and social care. Collaborative working is key to achieving these goals.
STPs encompass a variety of stakeholders ranging from representatives of Academic Health Science Networks (AHSNs), clinicians and pharmacists to local authority officers, charities and patient groups. Indeed, many local authority officers hold key posts in STPs as well as clinicians. These stakeholders attend key decision-making meetings and group consensus is often required in many STP areas before any significant changes can be implemented.
Some of these stakeholders are new to pharma and in order to engage with them it must do more than simply sell products – it must gain their trust in its shared values and philosophy. It must also demonstrate that it has a huge amount of expertise in specific diseases and therapies, and can lend support in areas such as providing real world evidence to inform patient pathway development and optimal care.
Medicines management staff within the locality may be involved in workstream planning groups led by programme managers to design new care pathways. They are very much involved in decision making, however, they work as part of a team, considering the whole implications of care and cost across the pathway.
Interestingly, the latest NHS Planning Guidance 2018-19, indicates there may be more room for transformative pathways, including medicines with STPs, as the system control total eases the history of tension and disagreement over NHS trusts’ budgetary accountability to NHS Improvement and CCGs’ budget accountability to NHS England.
Integrated Care Systems (ICSs)
Integrated care systems (ICSs) bring together NHS providers, commissioners and local authorities to work in partnership in improving health and care in their area. They will take the lead in planning and delivering care for their populations and providing system leadership.
Key decision-makers in ICSs will grow out of STPs, Vanguards and other new care models, such as primary and acute care systems (PACS) and multispecialty community providers (MCPs), which both seek to integrate care and improve population health. PACS and MCPs take different forms in different places but share a focus on places and populations rather than organisations.
A lot of service improvement managers currently employed by Clinical Commissioning Groups (CCGs) may transition over to work on the provider side in ICSs to ensure transformation happens, or they may work in an alliance within the ICS. A similar situation is likely to occur with middle managers in CCGs; while senior commissioning managers and executive managers may take on new roles as strategic commissioners within CCGs or STPs.
In terms of engagement, it is currently a complex and changing picture for pharma. The way services are planned will depend on factors ranging from what has happened in the past and what facilities are currently available to who is in charge, and whether it is an urban or rural location. Keeping a close watch on the developments in each locality will be key and will require cutting edge Customer Relationship Management (CRM) tools, combined with effective real time insight feeds to analyse the impact of changes.
Conclusion
Pharma must keep abreast of new care models that are emerging in different areas across England, be mindful of the variety of responsibilities that key customers hold and take a tailored approach to engagement across different geographical areas and with individual clinicians. Pharma must also sell its company and its philosophy to other key stakeholders and keep abreast of their activities in relevant disease and therapy areas.
Ends
Paul Midgley is Director of NHS insight, Sue Thomas is CEO of the Commissioning Excellence Directorate, Steve How is Business Development Director and Oli Hudson is Content Director, all at Wilmington Healthcare. For information on Wilmington Healthcare, log on to www.wilmingtonhealthcare.com
Company Details
Wilmington Healthcare
01268 495600
Address:
Beechwood House
2-3 Commercial Way
Christy Close
Southfields
Basildon
SS15 6EF
United Kingdom
Latest content on this profile
- Covid-19: how is it impacting on the NHS Long-term Plan?
- Oli Hudson and Paul Midgley, of Wilmington Healthcare, explain how coronavirus has expedited some parts of the plan but put others in jeopardy
Wilmington Healthcare
- Covid-19: what could it mean for the diabetic population?
- Steve How and Oli Hudson, of Wilmington Healthcare, assess the scale of the diabetes crisis and how coronavirus might impact on it
Wilmington Healthcare
- Delivering true value: what does it mean for KAM in cancer care?
- Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve
Wilmington Healthcare
- How will the Tories’ historic win shape the NHS?
- Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore the impact of December’s General Election result on 2020 and beyond
Wilmington Healthcare
- 2019: A pivotal year for the NHS
- Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore some of the key changes in the NHS in 2019
Wilmington Healthcare
- Early diagnosis underpins NHS cancer strategy
- Paul Midgley, Oli Hudson and Sarah Shield, of Wilmington Healthcare, explore how the NHS is tackling cancer in line with the Long-term Plan
Wilmington Healthcare
